Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence
2017 ◽
Vol 35
(6)
◽
pp. 692-692
◽
2018 ◽
Vol 7
(S2)
◽
pp. S134-S137
◽
2011 ◽
Vol 9
(1)
◽
pp. 2
◽